A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
A phase 3 trial of Capecitabine, Eribulin and Gemcitabine in HER2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06957886 by Sichuan Baili Pharmaceutical Co., Ltd., with 566 participants planned, started 2025-05-15 and due to reach its primary completion in 2027-05. Interventions recorded: BL-M07D1 and Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Eribulin, SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
- TrialA Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
Shares SystImmune / Sichuan Biokin, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Capecitabine and the tag pipeline.